Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 459-463

  Tabata, Shinsuke ^a   Goi, Takanori ^a   Nakazawa, Toshiyuki ^a   Kimura, Youhei ^a   Katayama, Kanji ^a   Yamaguchi, Akio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Colon cancer; Endocrine gland derived vascular endothelial growth factor; Invasion

Indexed keywords

ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; GELATINASE A; GELATINASE B; GROWTH FACTOR RECEPTOR; MATRILYSIN; MESSENGER RNA; PROTEIN PK R1; PROTEIN PK R2; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL STRAIN HCT116; COLON CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS;

ANTIBODIES; CELL MOVEMENT; COLONIC NEOPLASMS; GASTROINTESTINAL HORMONES; GENE EXPRESSION; HCT116 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR, ENDOCRINE-GLAND-DERIVED;

EID: 84872814210     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2124     Document Type: Article

References (32)

1. Muto T, Kotake K and Koyama Y: Colorectal cancer statistics in Japan: data from JSCCR registration, 1974-1993. Int J Clin Oncol 6: 171-176, 2001. (Pubitemid 32899617)
2. Koyama Y and Kotake K: Overview of colorectal cancer in Japan: report from the Registry of the Japanese Society for Cancer of the Colon and Rectum. Dis Colon Rectum 40: 2-9, 1997.
3. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994. (Pubitemid 24324908)
4. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller GA, et al: Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412: 877-884, 2001. (Pubitemid 32821726)
5. Soga T, Matsumoto S, Oda T, Saito T, Hijama H, Takasaki J, Kamohara M, Ohishi T, Matsushime H and Furuichi K: Molecular cloning and characterization of prokineticin receptors. Biochim Biophys Acta 1579: 173-179, 2002. (Pubitemid 35341439)
6. Lin DC, Bullock CM, Eheler FJ, Chen JL, Tian H and Zhou QY: Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 277: 19276-19280, 2002. (Pubitemid 34967431)
7. Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi Y, Suenaga M, Abe M, Fukusumi S, Watanabe T, Shintani Y, et al: Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors. Biochem Biophys Res Commun 293: 396-402, 2002. (Pubitemid 34694220)
8. Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H and Furukawa K: Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer 77: 466-471, 1998. (Pubitemid 28044053)
9. Yamaguchi A, Urano T, Goi T, Saito M, Takeuchi K, Hirose K, Nakagawara G, Shiku H and Furukawa K: Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 14: 1122-1127, 1996. (Pubitemid 26105518)
10. Fujishima Y, Goi T, Kimura Y, Hirono Y, Katayama K and Yamaguchi A: MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer. Int J Oncol 40: 960-964, 2012.
11. Sawai K, Goi T, Hirono Y, Katayama K and Yamaguchi A: Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res 18: 541-547, 2010.
12. Goi T, Yamaguchi A, Takeuchi K, Nakagawa G, Yamashiro S, Furukawa K, Urano T and Shiku H: CD44 with variant exons 8-10 in colorectal tumors: expression analysis by a variant exon 9-specific monoclonal antibody. Int J Oncol 8: 657-662, 1996. (Pubitemid 26111276)
13. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. (Pubitemid 36749215)
14. Sakurai T and Kudo M: Signaling pathways governing tumor angiogenesis. Oncology 81: 24-29, 2011.
15. Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 18: 4-25, 1997. (Pubitemid 27076453)
16. Andrae J, Gallini R and Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312, 2008. (Pubitemid 351717519)
17. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
18. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544, 2007. (Pubitemid 46733080)
19. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048, 2007. (Pubitemid 350106711)
20. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004. (Pubitemid 38944402)
21. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, Rougier P, Cunningham D, Nippgen J and Kohne C: Randomized phase III study of irinotecan and 5-FU/LV with or without cetuximab in the first line treatment of patients with metastatic colorectal cancer. J Clin Oncol 25: 4000, 2007.
22. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658-1664, 2007. (Pubitemid 46797944)
23. Nagano H, Goi T, Koneri K, Hirono Y, Katayama K and Yamaguchi A: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer. J Surg Oncol 96: 605-610, 2007. (Pubitemid 350191486)
24. Goi T, Fujioka M, Satoh Y, Tabata S, Koneri K, Nagano H, Hirono Y, Katayama K, Hirose K and Yamaguchi A: Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine gland-derived-vascular endothelial growth factor, as a new angiogenic factor. Cancer Res 64: 1906-1910, 2004. (Pubitemid 38339431)
25. Ngan ES, Sit FY, Lee K, Miao X, Yuan Z, Wang W, Nicholls JM, Wong KK, Garcia-Barcelo M, Lui VC and Tam PK: Implications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progression. Clin Cancer Res 13: 868-875, 2007. (Pubitemid 46340361)
26. Pasquali D, Rossi V, Staibano S, De Rosa G, Chieffi P, Prezioso D, Mirone V, Mascolo M, Tramontano D, Bellastella A and Sinisi AA: The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/ prokineticin 1 and 2 and receptor expression in human prostate: up-regulation of EG-VEGF/prokineticin 1 with malignancy. Endocrinology 147: 4245-4251, 2006. (Pubitemid 44268375)
27. Morales A, Vilchis F, Chávez B, Chan C, Robles-Díaz G and Díaz-Sánchez V: Expression and localization of endocrine gland-derived vascular endothelial growth factor (EG-VEGF) in human pancreas and pancreatic adenocarcinoma. J Steroid Biochem Mol Biol 107: 37-41, 2007. (Pubitemid 47362669)
28. Jiang X, Abiatari I, Kong B, Erkan M, De Oliveira T, Giese NA, Michalski C W, Friess H and Kleeff J: Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. Pancreatology 9: 165-172, 2009.
29. Chakraborti S, Mandal M, Das S, Mandal A and Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253: 269-285, 2003.
30. Rydlova M, Holubec L Jr, Ludvikova M Jr, Kalfert D, Franekova J, Povysil C and Ludvikova M: Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 28: 1389-1397, 2008. (Pubitemid 351578885)
31. Zucker S and Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23: 101-117, 2004. (Pubitemid 38221598)
32. Tomita T and Iwata K: Matrix metaIloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas. Dis Colon Rectum 39: 1255-1264, 1996. (Pubitemid 26389536)